Resbiotic Spins Out Pharmaceutical Subsidiary Alveolus Bio, Raises $4.5M Seed Funding And Launches First Consumer Health Product
Amount Raised
$4.5 Million
Round Type
Seed
BirminghamHealthcareHealth Carehealth, wellness & fitnessDescription
Birmingham, Alabama-based biotech startup ResBiotic today announced the spin-out of its drug development arm, Alveolus Bio, and the launch of its first consumer health product, resB® Lung Support. With $4.5M in seed funding, ResBiotic and Alveolus Bio are poised to transform the respiratory care landscape and chart new frontiers for microbiome science.
Who to call at Resbiotic, and when
A new round usually means Resbiotic is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Resbiotic raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Resbiotic, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Resbiotic. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Resbiotic raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Resbiotic raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.